Restricted accessResearch articleFirst published online 2015-12
The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34 + Hematopoietic Stem and Progenitor Cells
Early natural killer (NK)-cell repopulation after allogeneic stem cell transplantation (allo-SCT) has been associated with reduced relapse rates without an increased risk of graft-versus-host disease, indicating that donor NK cells have specific antileukemic activity. Therefore, adoptive transfer of donor NK cells is an attractive strategy to reduce relapse rates after allo-SCT. Since NK cells of donor origin will not be rejected, multiple NK-cell infusions could be administered in this setting. However, isolation of high numbers of functional NK cells from transplant donors is challenging. Hence, we developed a cytokine-based ex vivo culture protocol to generate high numbers of functional NK cells from granulocyte colony-stimulating factor (G-CSF)-mobilized CD34+ hematopoietic stem and progenitor cells (HSPCs). In this study, we demonstrate that addition of aryl hydrocarbon receptor antagonist StemRegenin1 (SR1) to our culture protocol potently enhances expansion of CD34+ HSPCs and induces expression of NK-cell-associated transcription factors promoting NK-cell differentiation. As a result, high numbers of NK cells with an active phenotype can be generated using this culture protocol. These SR1-generated NK cells exert efficient cytolytic activity and interferon-γ production toward acute myeloid leukemia and multiple myeloma cells. Importantly, we observed that NK-cell proliferation and function are not inhibited by cyclosporin A, an immunosuppressive drug often used after allo-SCT. These findings demonstrate that SR1 can be exploited to generate high numbers of functional NK cells from G-CSF-mobilized CD34+ HSPCs, providing great promise for effective NK-cell-based immunotherapy after allo-SCT.
Get full access to this article
View all access options for this article.
References
1.
LjunggrenHG and MalmbergKJ. (2007). Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol, 7:329–339.
2.
MillerJS, SoignierY, Panoskaltsis-MortariA, McNearneySA, YunGH, FautschSK, McKennaD, LeC, DeforTE, et al. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105:3051–3057.
3.
CurtiA, RuggeriL, D'AddioA, BontadiniA, DanE, MottaMR, TrabanelliS, GiudiceV, UrbaniE, et al. (2011). Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 118:3273–3279.
4.
RubnitzJE, InabaH, RibeiroRC, PoundsS, RooneyB, BellT, PuiCH and LeungW. (2010). NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol, 28:955–959.
5.
SpanholtzJ, PreijersF, TordoirM, TrilsbeekC, PaardekooperJ, de WitteT, SchaapN and DolstraH. (2011). Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One, 6:e20740.
6.
SpanholtzJ, TordoirM, EissensD, PreijersF, van der MeerA, JoostenI, SchaapN, de WitteTM and DolstraH. (2010). High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One, 5:e9221.
7.
CanyJ, van der WaartAB, TordoirM, FranssenGM, HangalapuraBN, de VriesJ, BoermanO, SchaapN, van der VoortR, SpanholtzJ and DolstraH. (2013). Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS One, 8:e64384.
8.
BaronF, PetersdorfEW, GooleyT, SandmaierBM, MalkkiM, ChaunceyTR, MaloneyDG and StorbR. (2009). What is the role for donor natural killer cells after nonmyeloablative conditioning?. Biol Blood Marrow Transplant, 15:580–588.
9.
SavaniBN, MielkeS, AdamsS, UribeM, RezvaniK, YongAS, ZeilahJ, KurlanderR, SrinivasanR, et al. (2007). Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia, 21:2145–2152.
10.
TanakaM, KobayashiS, NumataA, TachibanaT, TakasakiH, MarutaA, IshigatsuboY and KanamoriH. (2012). The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. Leuk Res, 36:699–703.
11.
SymonsHJ, LeffellMS, RossiterND, ZahurakM, JonesRJ and FuchsEJ. (2010). Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant, 16:533–542.
12.
CooleyS, TrachtenbergE, BergemannTL, SaeteurnK, KleinJ, LeCT, MarshSG, GuethleinLA, ParhamP, MillerJS and WeisdorfDJ. (2009). Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood, 113:726–732.
13.
KrogerN, ZabelinaT, BergerJ, DuskeH, KlyuchnikovE, BinderT, StubigT, Hilde-brandtY, AtanackovicD, et al. (2011). Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia, 25:1657–1661.
14.
BoitanoAE, WangJ, RomeoR, BouchezLC, ParkerAE, SuttonSE, WalkerJR, FlavenyCA, PerdewGH, et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science, 329:1345–1348.
15.
NguyenLP and BradfieldCA. (2008). The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol, 21:102–116.
16.
MimuraJ and Fujii-KuriyamaY. (2003). Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta, 1619:263–268.
17.
LiuH, RamachandranI and GabrilovichDI. (2014). Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunol Cell Biol, 92:200–203.
18.
ThordardottirS, HangalapuraBN, HuttenT, CossuM, SpanholtzJ, SchaapN, RadstakeTR, VoortRV and DolstraH. (2014). The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34 hematopoietic progenitor cells. Stem Cells Dev, 23:955–967.
19.
GandhiR, KumarD, BurnsEJ, NadeauM, DakeB, LaroniA, KozorizD, WeinerHL and QuintanaFJ. (2010). Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol, 11:846–853.
20.
HaubenE, GregoriS, DraghiciE, MigliavaccaB, OlivieriS, WoisetschlagerM and RoncaroloMG. (2008). Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood, 112:1214–1222.
21.
KadowS, JuxB, ZahnerSP, WingerathB, ChmillS, ClausenBE, HengstlerJ and EsserC. (2011). Aryl hydrocarbon receptor is critical for homeostasis of invariant gammadelta T cells in the murine epidermis. J Immunol, 187:3104–3110.
22.
VeldhoenM, HirotaK, WestendorfAM, BuerJ, DumoutierL, RenauldJC and StockingerB. (2008). The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature, 453:106–109.
23.
HughesT, BriercheckEL, FreudAG, TrottaR, McCloryS, ScovilleSD, KellerK, DengY, ColeJ, et al. (2014). The transcription factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. Cell Rep, 8:150–162.
24.
OveresIM, de RijkeB, van Horssen-ZoetbroodA, FredrixH, de GraafAO, JansenJH, van KriekenJH, RaymakersRA, van der VoortR, de WitteTM and DolstraH. (2008). Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol, 141:799–807.
25.
JedemaI, van der WerffNM, BargeRM, WillemzeR and FalkenburgJH. (2004). New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood, 103:2677–2682.
26.
NordeWJ, OveresIM, MaasF, FredrixH, VosJC, KesterMG, van der VoortR, JedemaI, FalkenburgJH, et al. (2009). Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood, 113:2312–2323.
27.
AliahmadP, de la TorreB and KayeJ. (2010). Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol, 11:945–952.
28.
BoosMD, YokotaY, EberlG and KeeBL. (2007). Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med, 204:1119–1130.
29.
GordonSM, ChaixJ, RuppLJ, WuJ, MaderaS, SunJC, LindstenT and ReinerSL. (2012). The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity, 36:55–67.
30.
SamsonSI, RichardO, TavianM, RansonT, VosshenrichCA, ColucciF, BuerJ, GrosveldF, GodinI and Di SantoJP. (2003). GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity, 19:701–711.
31.
Perez-QuinteroLA, RoncagalliR, GuoH, LatourS, DavidsonD and VeilletteA. (2014). EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cgamma, Ca++, and Erk, leading to granule polarization. J Exp Med, 211:727–742.
32.
LehmannD, SpanholtzJ, OslM, TordoirM, LipnikK, BilbanM, SchlechtaB, DolstraH and HoferE. (2012). Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem Cells Dev, 21:2926–2938.
33.
GrzywaczB, KatariaN, SikoraM, OostendorpRA, DzierzakEA, BlazarBR, MillerJS and VernerisMR. (2006). Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood, 108:3824–3833.
34.
BeiderK, NaglerA, WaldO, FranitzaS, Dagan-BergerM, WaldH, GiladiH, BrockeS, HannaJ, et al. (2003). Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood, 102:1951–1958.
35.
ChenS, KawashimaH, LoweJB, LanierLL and FukudaM. (2005). Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med, 202:1679–1689.
36.
StorekJ, DawsonMA, StorerB, Stevens-AyersT, MaloneyDG, MarrKA, WitherspoonRP, BensingerW, FlowersME, et al. (2001). Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood, 97:3380–3389.
37.
BrownMG, DokunAO, HeuselJW, SmithHR, BeckmanDL, BlattenbergerEA, DubbeldeCE, StoneLR, ScalzoAA and YokoyamaWM. (2001). Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science, 292:934–937.
38.
FoleyB, CooleyS, VernerisMR, PittM, CurtsingerJ, LuoX, Lopez-VergesS, LanierLL, WeisdorfD and MillerJS. (2012). Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood, 119:2665–2674.
39.
FoleyB, CooleyS, VernerisMR, CurtsingerJ, LuoX, WallerEK, WeisdorfDJ and MillerJS. (2011). NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood, 118:2784–2792.
40.
JuelkeK, KilligM, ThielA, DongJ and RomagnaniC. (2009). Education of hyporesponsive NK cells by cytokines. Eur J Immunol, 39:2548–2555.
41.
EissensDN, Van Der MeerA, Van CranenbroekB, PreijersFW and JoostenI. (2010). Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant, 10:1981–1990.
42.
WangH, GrzywaczB, SukovichD, McCullarV, CaoQ, LeeAB, BlazarBR, CornfieldDN, MillerJS and VernerisMR. (2007). The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood, 110:1530–1539.
43.
MillerJS, AlleyKA and McGlaveP. (1994). Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood, 83:2594–2601.
44.
MrozekE, AndersonP and CaligiuriMA. (1996). Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood, 87:2632–2640.
45.
YoonSR, LeeYS, YangSH, AhnKH, LeeJH, LeeJH, KimDY, KangYA, JeonM, et al. (2010). Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant, 45:1038–1046.
46.
ShiJ, TricotG, SzmaniaS, RosenN, GargTK, MalaviarachchiPA, MorenoA, DupontB, HsuKC, et al. (2008). Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol, 143:641–653.
47.
ChoiI, YoonSR, ParkSY, KimH, JungSJ, JangYJ, KangM, YeomYI, LeeJL, et al. (2014). Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant, 20:696–704.
48.
PasswegJR, TichelliA, Meyer-MonardS, HeimD, SternM, KuhneT, FavreG and GratwohlA. (2004). Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia, 18:1835–1838.
49.
KoehlU, BrehmC, HueneckeS, ZimmermannSY, KloessS, BremmM, UllrichE, SoerensenJ, QuaiserA, et al. (2013). Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol, 3:118.
50.
McKennaDH, Jr., SumstadD, BostromN, KadidloDM, FautschS, McNearneyS, DewaardR, McGlavePB, WeisdorfDJ, et al. (2007). Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion, 47:520–528.
51.
WilsonCL and SafeS. (1998). Mechanisms of ligand-induced aryl hydrocarbon receptor-mediated biochemical and toxic responses. Toxicol Pathol, 26:657–671.
52.
DenisonMS and NagySR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol, 43:309–334.
53.
BessedeA, GargaroM, PallottaMT, MatinoD, ServilloG, BrunacciC, BicciatoS, MazzaEM, MacchiaruloA, et al. (2014). Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 511:184–190.
54.
CasadoFL, SinghKP and GasiewiczTA. (2010). The aryl hydrocarbon receptor: regulation of hematopoiesis and involvement in the progression of blood diseases. Blood Cells Mol Dis, 44:199–206.
55.
ShertzerHG and SenftAP. (2000). The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metabol Drug Interact, 17:159–188.
56.
LoweMM, MoldJE, KanwarB, HuangY, LouieA, PollastriMP, WangC, PatelG, FranksDG, et al. (2014). Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One, 9:e87877.
57.
WeiYD, HellebergH, RannugU and RannugA. (1998). Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole. Chem Biol Interact, 110:39–55.
58.
MezrichJD, FechnerJH, ZhangX, JohnsonBP, BurlinghamWJ and BradfieldCA. (2010). An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol, 185:3190–3198.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
